HomeCompareEVGRF vs JNJ

EVGRF vs JNJ: Dividend Comparison 2026

EVGRF yields 181818.18% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EVGRF wins by $1.8951031795759825e+29M in total portfolio value
10 years
EVGRF
EVGRF
● Live price
181818.18%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8951031795759825e+29M
Annual income
$189,305,502,041,192,720,000,000,000,000,000,000.00
Full EVGRF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — EVGRF vs JNJ

📍 EVGRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVGRFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVGRF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVGRF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVGRF
Annual income on $10K today (after 15% tax)
$15,454,545.45/yr
After 10yr DRIP, annual income (after tax)
$160,909,676,735,013,800,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, EVGRF beats the other by $160,909,676,735,013,800,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVGRF + JNJ for your $10,000?

EVGRF: 50%JNJ: 50%
100% JNJ50/50100% EVGRF
Portfolio after 10yr
$9.475515897879912e+28M
Annual income
$94,652,751,020,596,360,000,000,000,000,000,000.00/yr
Blended yield
99.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EVGRF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVGRF buys
0
JNJ buys
0
No recent congressional trades found for EVGRF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVGRFJNJ
Forward yield181818.18%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1.8951031795759825e+29M$30.5K
Annual income after 10y$189,305,502,041,192,720,000,000,000,000,000,000.00$4,749.88
Total dividends collected$1.8949690612486723e+29M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EVGRF vs JNJ ($10,000, DRIP)

YearEVGRF PortfolioEVGRF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$18,192,518$18,181,818.18$10,594$274.49+$18.18MEVGRF
2$30,932,835,887$30,913,369,892.64$11,294$360.69+$30932.82MEVGRF
3$49,156,619,660,049$49,123,521,525,649.34$12,133$476.91+$49156619.65MEVGRF
4$73,009,768,971,452,110$72,957,171,388,415,860.00$13,156$635.42+$73009768971.44MEVGRF
5$101,348,671,691,011,770,000$101,270,551,238,212,300,000.00$14,432$854.61+$101348671691011.75MEVGRF
6$131,490,628,941,834,950,000,000$131,382,185,863,125,600,000,000.00$16,056$1,162.76+$131490628941834960.00MEVGRF
7$159,445,709,700,484,420,000,000,000$159,305,014,727,516,640,000,000,000.00$18,175$1,604.53+$159445709700484431872.00MEVGRF
8$180,706,560,655,892,340,000,000,000,000$180,535,953,746,512,850,000,000,000,000.00$21,009$2,252.68+$1.8070656065589233e+23MEVGRF
9$191,416,744,304,199,340,000,000,000,000,000$191,223,388,284,297,560,000,000,000,000,000.00$24,911$3,229.73+$1.9141674430419936e+26MEVGRF
10$189,510,317,957,598,240,000,000,000,000,000,000$189,305,502,041,192,720,000,000,000,000,000,000.00$30,458$4,749.88+$1.8951031795759825e+29MEVGRF

EVGRF vs JNJ: Complete Analysis 2026

EVGRFStock

China Evergrande New Energy Vehicle Group Limited, an investment holding company, operates as a health management company in the People's Republic of China, Europe, and internationally. The company operates through two segments, Health Management and New Energy Vehicle. It develops and sells health and living properties; and provides community health management, medical cosmetology, and anti-aging services, as well as elderly care and rehabilitation. The company is involved in the wholesale of home care and healthcare products, as well as provision of healthcare services and software services. In addition, it engages in the research and development of pharmaceuticals; production of medical equipment; and manufacture and sale of smart mobility and lithium-ion battery. Further, the company is involved in the research, development, production, and sales of new energy vehicles and vehicle living project. The company was formerly known as Evergrande Health Industry Group Limited and changed its name to China Evergrande New Energy Vehicle Group Limited in August 2020. China Evergrande New Energy Vehicle Group Limited was founded in 1999 and is headquartered in Guangzhou, China. China Evergrande New Energy Vehicle Group Limited is a subsidiary of China Evergrande Group.

Full EVGRF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this EVGRF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVGRF vs SCHDEVGRF vs JEPIEVGRF vs OEVGRF vs KOEVGRF vs MAINEVGRF vs ABBVEVGRF vs MRKEVGRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.